Peptide News Digest

#Amgn

2 stories

Industry · View digest

Amgen (NASDAQ: AMGN) Follows Tuesday Q2 Beat With Wednesday August 5 Disclosure That the Company Is Ending Development of AMG 513, an Early-Stage Obesity Candidate; The Discontinuation Allows the MariTide (Maridebart Cafraglutide) Monthly-Injectable Antibody-Peptide Conjugate for Obesity to Remain the Sole Obesity Focus in the Amgen Pipeline; Amgen's Full-Year 2026 Guidance Raised to $38.2-39.4 Billion Revenue (Midpoint $38.8 Billion vs $37.7 Billion Consensus) With Continued Analyst Focus on the Upcoming MariTide, Olpasiran, and Xaluritamig Data Readouts as Key Drivers of Growth Beyond the Established Repatha, EVENITY, and TEZSPIRE Franchises

Amgen (NASDAQ: AMGN) followed its Tuesday August 4, 2026 Q2 earnings beat with the Wednesday August 5 disclosure that the company is ending development of AMG 513, an early-stage obesity candidate. The discontinuation allows MariTide (maridebart cafraglutide, the monthly-injectable antibody-peptide conjugate targeting GLP-1 and GIP receptors) to remain the sole obesity focus in the Amgen pipeline as it advances through the Phase 3 MARITIME program (MARITIME-1 obesity, MARITIME-CV cardiovascular outcomes, MARITIME-HF heart failure). Amgen's Q2 2026 revenue reached $10.05 billion (+10% YoY) with adjusted EPS of $6.29 (+4% YoY, beating the $5.62 consensus). Full-year 2026 guidance was raised to $38.2-39.4 billion revenue (midpoint $38.8 billion versus $37.7 billion consensus) with adjusted EPS guidance of $22.30-23.50. Management emphasized the potential of upcoming data readouts for MariTide, Olpasiran (Lp(a)-lowering siRNA), and Xaluritamig (prostate cancer BiTE) to drive future growth beyond the established Repatha (PCSK9), EVENITY (osteoporosis), TEZSPIRE (severe asthma), and UPLIZNA (neuromyelitis optica) franchises. AMG 513 mechanism and stage details were not extensively disclosed, but the discontinuation signals disciplined pipeline management focused on the higher-conviction MariTide bet.

Industry · View digest

Amgen (NASDAQ: AMGN) Q2 2026 Earnings Tuesday August 4 Beat Consensus and Raised Full-Year 2026 Revenue Guidance to $38.2-39.4 Billion (Midpoint $38.8 Billion Above the $37.7 Billion Consensus) With Adjusted EPS Guidance $22.30-23.50 (Midpoint $22.90 Above the $22.35 Consensus); Growth Drivers Include Repatha (Evolocumab PCSK9 Antibody) at $953 Million (+37% YoY), EVENITY at $714 Million (+38%), TEZSPIRE at $486 Million (+42%), and UPLIZNA at $335 Million (+90%); MariTide Phase 3 Obesity Program Continues Advancing With Multiple Trials Across Weight Management, Cardiovascular Outcomes, and Heart Failure Indications Though Cantor Fitzgerald Flagged a 4% Bone Mineral Density Decline From Phase 1 Data as a Potential Safety Concern

Amgen (NASDAQ: AMGN) reported Q2 2026 earnings Tuesday August 4, 2026 with a beat and raised full-year 2026 revenue guidance to $38.2-39.4 billion (midpoint $38.8 billion above the $37.7 billion analyst consensus). Adjusted EPS guidance is $22.30-23.50 (midpoint $22.90 above the $22.35 consensus). Growth-portfolio product performance drove the beat: Repatha (evolocumab, PCSK9 monoclonal antibody) reached $953 million (+37% year-over-year); EVENITY (romosozumab for osteoporosis) $714 million (+38%); TEZSPIRE (tezepelumab for severe asthma) $486 million (+42%); UPLIZNA (inebilizumab for neuromyelitis optica spectrum disorder) $335 million (+90%). The MariTide (maridebart cafraglutide, monthly-injectable antibody-peptide conjugate targeting GLP-1 and GIPR) Phase 3 obesity program continues advancing with multiple trials across weight management, cardiovascular outcomes, and heart failure indications; earnings-call commentary described 2026 as a year of disciplined MariTide data generation. Analyst scrutiny remains on the 4% bone mineral density decline observed in Phase 1 MariTide data (per Cantor Fitzgerald analysis) as a potential regulatory hurdle and safety disadvantage versus GLP-1 receptor agonist competitors. Amgen shares closed up 3.03% on August 4.